CN104093712B - 作为糖原合酶激酶3β抑制剂的1H-吲唑-3-甲酰胺化合物 - Google Patents

作为糖原合酶激酶3β抑制剂的1H-吲唑-3-甲酰胺化合物 Download PDF

Info

Publication number
CN104093712B
CN104093712B CN201380007411.7A CN201380007411A CN104093712B CN 104093712 B CN104093712 B CN 104093712B CN 201380007411 A CN201380007411 A CN 201380007411A CN 104093712 B CN104093712 B CN 104093712B
Authority
CN
China
Prior art keywords
alkyl
alkoxy
indazole
halogen
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380007411.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104093712A (zh
Inventor
M·A·阿利斯
N·卡佐拉
P·德拉戈内
G·弗尔罗逖
C·毛杰里
R·翁布拉托
F·曼茨尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of CN104093712A publication Critical patent/CN104093712A/zh
Application granted granted Critical
Publication of CN104093712B publication Critical patent/CN104093712B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380007411.7A 2012-02-21 2013-02-07 作为糖原合酶激酶3β抑制剂的1H-吲唑-3-甲酰胺化合物 Active CN104093712B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12156292 2012-02-21
EP12156292.0 2012-02-21
PCT/EP2013/052400 WO2013124158A1 (en) 2012-02-21 2013-02-07 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Publications (2)

Publication Number Publication Date
CN104093712A CN104093712A (zh) 2014-10-08
CN104093712B true CN104093712B (zh) 2016-11-09

Family

ID=47739223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380007411.7A Active CN104093712B (zh) 2012-02-21 2013-02-07 作为糖原合酶激酶3β抑制剂的1H-吲唑-3-甲酰胺化合物

Country Status (26)

Country Link
US (3) US9611249B2 (enExample)
EP (1) EP2817302B1 (enExample)
JP (1) JP6141331B2 (enExample)
KR (1) KR20140130124A (enExample)
CN (1) CN104093712B (enExample)
AR (1) AR090086A1 (enExample)
AU (1) AU2013224302B2 (enExample)
BR (1) BR112014018655B1 (enExample)
CA (1) CA2860250C (enExample)
CY (1) CY1117469T1 (enExample)
DK (1) DK2817302T3 (enExample)
EA (1) EA024939B1 (enExample)
ES (1) ES2564961T3 (enExample)
GE (1) GEP20166489B (enExample)
HR (1) HRP20160125T1 (enExample)
HU (1) HUE026893T2 (enExample)
IL (1) IL233824A (enExample)
ME (1) ME02353B (enExample)
MX (1) MX351287B (enExample)
PL (1) PL2817302T3 (enExample)
RS (1) RS54567B1 (enExample)
SG (2) SG11201403602WA (enExample)
SI (1) SI2817302T1 (enExample)
SM (1) SMT201600053B (enExample)
UA (1) UA112564C2 (enExample)
WO (1) WO2013124158A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860466C (en) * 2012-02-21 2020-02-18 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S.P.A. Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2942687A1 (en) 2014-03-20 2015-09-24 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
AU2017272505B9 (en) 2016-06-01 2021-10-28 Bayer Pharma Aktiengesellschaft Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
CN109563071B (zh) * 2016-06-08 2021-08-03 葛兰素史密斯克莱知识产权发展有限公司 作为atf4途径抑制剂的化学化合物
SG11202008029UA (en) * 2018-02-23 2020-09-29 Samumed Llc 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof
IL278330B2 (en) 2018-05-07 2024-06-01 Acraf 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
IL279155B2 (en) 2018-06-05 2025-02-01 Actuate Therapeutics Inc Methods for treating malignant lymphoid tissue proliferation disorders
US12084426B2 (en) 2018-09-13 2024-09-10 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
EA202190718A1 (ru) 2018-09-13 2021-07-01 Бристол-Маерс Сквибб Компани Индазолкарбоксамиды в качестве ингибиторов киназ
US20240051939A1 (en) * 2020-12-08 2024-02-15 Disarm Therapeutics, Inc. Benzopyrazole inhibitors of sarm1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014554A1 (en) * 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
CN1742004A (zh) * 2003-02-18 2006-03-01 方济各安吉利克化学联合股份有限公司 具有止痛活性的吲唑酰胺类
WO2008154241A1 (en) * 2007-06-08 2008-12-18 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705498A (en) 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
EP1546156A1 (en) * 2002-08-10 2005-06-29 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
EP1692939A1 (en) * 2005-02-19 2006-08-23 Bayer CropScience S.A. Pesticidal substituted piperidines
UA99927C2 (uk) 2007-11-12 2012-10-25 Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. Медикамент, який є активним при невропатичному болі
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US7947728B1 (en) * 2009-11-11 2011-05-24 Hoffmann-La Roche Inc. Indole and indazole analogs as glycogen synthase activators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1742004A (zh) * 2003-02-18 2006-03-01 方济各安吉利克化学联合股份有限公司 具有止痛活性的吲唑酰胺类
WO2005014554A1 (en) * 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
WO2008154241A1 (en) * 2007-06-08 2008-12-18 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors

Also Published As

Publication number Publication date
BR112014018655A8 (pt) 2017-07-11
AU2013224302A1 (en) 2014-07-17
CY1117469T1 (el) 2017-04-26
GEP20166489B (en) 2016-06-10
EP2817302A1 (en) 2014-12-31
AU2013224302B2 (en) 2017-03-30
ME02353B (me) 2016-06-20
US20170174657A1 (en) 2017-06-22
HRP20160125T1 (hr) 2016-03-11
MX351287B (es) 2017-10-09
EP2817302B1 (en) 2015-12-30
HUE026893T2 (en) 2016-07-28
SG10201701649YA (en) 2017-04-27
RS54567B1 (sr) 2016-06-30
US20150057294A1 (en) 2015-02-26
MX2014009297A (es) 2014-08-27
EA024939B1 (ru) 2016-11-30
BR112014018655A2 (enExample) 2017-06-20
US9611249B2 (en) 2017-04-04
CA2860250C (en) 2020-11-10
HK1203930A1 (zh) 2015-11-06
SG11201403602WA (en) 2014-07-30
JP6141331B2 (ja) 2017-06-07
EA201491449A1 (ru) 2014-11-28
JP2015506993A (ja) 2015-03-05
CN104093712A (zh) 2014-10-08
CA2860250A1 (en) 2013-08-29
US20170157121A1 (en) 2017-06-08
SI2817302T1 (sl) 2016-03-31
SMT201600053B (it) 2016-04-29
DK2817302T3 (en) 2016-03-21
KR20140130124A (ko) 2014-11-07
BR112014018655B1 (pt) 2022-02-08
WO2013124158A1 (en) 2013-08-29
PL2817302T3 (pl) 2016-06-30
AR090086A1 (es) 2014-10-15
US10160746B2 (en) 2018-12-25
IL233824A (en) 2016-09-29
UA112564C2 (uk) 2016-09-26
IL233824A0 (en) 2014-09-30
ES2564961T3 (es) 2016-03-30

Similar Documents

Publication Publication Date Title
CN104093712B (zh) 作为糖原合酶激酶3β抑制剂的1H-吲唑-3-甲酰胺化合物
CN104080781B (zh) 1H-吲唑-3-甲酰胺化合物作为糖原合酶激酶3β抑制剂的用途
CN101790526A (zh) 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
KR20100016511A (ko) 아릴아미드 피리미돈 화합물
CN108349956A (zh) 吡啶酮衍生物及其作为激酶抑制剂的用途
HK1203930B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
HK1203931B (en) Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant